Cargando…
Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new term from nonalcoholic fatty liver disease (NAFLD) and is a positive diagnosis based on histopathology, imaging, or blood biomarkers. MAFLD is one of the common causes of liver dysfunction worldwide, likely due to the increase in...
Autores principales: | Prasoppokakorn, Thaninee, Pitisuttithum, Panyavee, Treeprasertsuk, Sombat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666366/ https://www.ncbi.nlm.nih.gov/pubmed/34966657 http://dx.doi.org/10.14218/JCTH.2021.00189 |
Ejemplares similares
-
Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2022) -
Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2022) -
Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis
por: Navadurong, Huttakan, et al.
Publicado: (2023) -
Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
por: Sangro, Paloma, et al.
Publicado: (2023) -
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)